SlideShare a Scribd company logo
1 of 65
FBW 
9-12-2014 
Wim Van Criekinge
Examen 
<html> 
<title>Examen Bioinformatica</title> 
<center> 
<head> 
<script> 
rnd.today=new Date(); 
rnd.seed=rnd.today.getTime(); 
function rnd() { 
rnd.seed = (rnd.seed*9301+49297) % 233280; 
return rnd.seed/(233280.0); 
}; 
function rand(number) { 
return Math.ceil(rnd()*number); 
}; 
</SCRIPT> 
</head> 
<body bgcolor="#FFFFFF" text="#00FF00" link="#00FF00"> 
<script language="JavaScript"> 
document.write('<table>'); 
document.write('<tr>'); 
document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" 
height="360"></a></td>'); 
rand(98); 
document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" 
height="360"></a></td>'); 
rand(98); 
document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" 
height="360"></a></td>'); 
rand(98); 
document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" 
height="360"></a></td>'); 
rand(98);
Comparative Genomics: The biological Rosetta 
• The keywords can be 
– genome structure 
– gene-organisation 
– known promoter regions 
– known critical amino acid residues. 
• Combination of functional 
modelorganism knowledge 
• Structure-function 
• Identify similar areas of biology 
• Identify orthologous pathways (might 
have different endpoints)
Example: Agro 
Sequence Genome 
Known “lethal” genes 
from worm, drosphila 
Filter for drugability”, 
tractibility & novelty
Example: Extremophiles 
Known lipases 
Filter for 
“workable”lipases 
at 90º C 
Look for species 
with interesting 
phenotypes 
Functional Foods 
Convert Highly Energetic Monosaccharides to Dextrane 
Washing Powder additives 
Sequence Genome 
Clone and produce in large quantities
Drug Discovery: Design new drugs by computer ? 
Problem: pipeline cost rise linear, NCE steady 
Money: bypassing difficult, work on attrition 
Every step requires specific computational tools
Drug Discovery: What is a drug ? 
• Drugs are generally defined as molecules which 
affect biological processes. 
• In order to be effective, the molecule must be 
present in the body at an adequate concentration 
for it to act at the specific site in the body where 
it can exert its effect. 
• Additionally, the molecule must be safe -- that 
is, metabolized and eliminated from the body 
without causing injury. 
• Assumption: next 50 years still a big market in 
small chemical entities which can be 
administered orally in form of a pill (in contrast 
to antibodies) or gene therapy …
• Taxol a drug which is an unmodified natural 
compound, is the exception 
• Most drugs require “work” -> need for target 
driven pipeline 
• Humane genome is available so all target are 
identified 
• How to validate (within a given disease area) ?
Drug Discovery: What is a target ? 
• target - a molecule (often a protein) that is instrumental 
to a disease process (though not necessarily directly 
involved), which may be targeted with a potential 
therapeutic. 
• target identification - identifying a molecule (often a 
protein) that is instrumental to a disease process (though 
not necessarily directly involved), with the intention of 
finding a way to regulate that molecule's activity for 
therapeutic purposes. 
• target validation - a crucial step in the drug 
development process. Following the identification of a 
potential disease target, target validation verifies that a 
drug that specifically acts on the target can have a 
significant therapeutic benefit in the treatment of a given 
disease.
Phenotypic Gap 
Total # genes 
# genes with 
known function 
Number of genes 
1980 1990 2000 2010 
Functional Genomics ? 
More than running chip experiments ! 
Proposal to prioritize 
hypothetical protein 
without annotation, nice 
for bioinformatics and 
biologist
Where is optimal drug target ? 
“Optimal” drug target 
Predict side effect 
How to correct disease state 
Side effects ?
Genome-wide RNAi 
RNAI vector 
bacteria producing ds RNA for 
each of the 20.000 genes 
proprietary nematode 
responding to RNAi 
20.000 responses 
20.000 genes insert 
library
Type-II Diabetes 
Normal insulin signaling 
fat storage LOW 
Reduced insulin signaling 
fat storage HIGH
Industrialized knock-downs 
20,000 bacteria 
each containing 
selected 
C. elegans gene 
proprietary C.elegans strains 
• sensitized to silencing 
• sensitized to relevant pathway 
select genes with desired phenotypes
Pharma is conservative
Structural Genomics 
Molecular functions of 26 383 human genes
Lipinsky for the target ? 
Database of all “drugable” human genes
Drug Discovery: Design new drugs by computer ?
Drug Discovery: Screening definitions 
screening - the automated examination and 
testing of libraries of synthetic and/or organic 
compounds and extracts to identify potential drug 
leads, based on the compound's binding affinity 
for a target molecule. 
screening library - a large collection of 
compounds with different chemical properties or 
shapes, generated either by combinatorial 
chemistry or some other process or by collecting 
samples with interesting biological properties. 
High Throughput Screening: Quick and Dirty… 
from 5000 compounds per day
Drug Discovery: Screening Throughput 
• At the beginning of the 1990s, when the 
term "high-throughput screening" was 
coined, a department of 20 would 
typically be able to screen around 1.5 
million samples in a year, each 
researcher handling around 75,000 
samples. Today, four researchers using 
fully automated robotic technology can 
screen 50,000 samples a day, or around 
2.5 million samples each year.
Robotic arm 
Drug Discovery: HTS – The Wet Lab 
Distribution 
96 / 384 wells 
Read-out 
Fluorescence / 
luminescence 
Optical Bank 
for stability
Drug Discovery: Chemistry Sources 
• Available molecules collections from pharma, 
chemical and agro industry, also from 
academics (Eastern Europe) 
• Natural products from fungi, algae, exotic 
plants, Chinese and ethnobotanic medicines 
• Combinatorial chemistry: it is the generation 
of large numbers of diverse chemical 
compounds (a library) for use in screening 
assays against disease target molecules. 
• Computer drug design (from model 
substrates or X-ray structure)
Drug Discovery 
HIT LEAD
• initial screen established 
• Compounds screened 
• IC50s established 
• Structures verified 
• Minimum of three independent 
chemical series to evaluate 
• Positive in silico PK data 
Drug Discovery: HIT
Drug Discovery: Hit/lead computational approaches 
• When the structure of the target is unknown, 
the activity data can be used to construct a 
pharmacophore model for the positioning of 
key features like hydrogen-bonding and 
hydrophobic groups. 
• Such a model can be used as a template to 
select the most promising candidates from the 
library.
• lead compound - a potential drug candidate emerging from a 
screening process of a large library of compounds. 
• It basically affects specifically a biological process. 
Mechanism of activity (reversible/ irreversible, kinetics) 
established 
• Its is effective at a low concentration: usually nanomolar 
activity 
• It is not toxic to live cells 
• It has been shown to have some in vivo activity 
• It is chemically feasible. Specificity of key compound(s) from 
each lead series against selected number of receptors/enzymes 
• Preliminary PK in vivo (rodent) to establish benchmark for in 
vitro SAR 
• In vitro PK data good predictor for in vivo activity 
• Its is of course New and Original. 
Drug Discovery: Lead ?
Lipinski: « rule of 5 » 
"In the USAN set we found that the sum of Ns and Os in the molecular formula was 
greater than 10 in 12% of the compounds. Eleven percent of compounds had 
a MWT of over 500. Ten percent of compounds had a CLogP larger than 5 (or 
an MLogP larger than 4.15) and in 8% of compounds the sum of OHs and NHs 
in the chemical structure was larger than 5. The "rule of 5" states that: poor 
absorption or permeation is more likely when: 
A. There are less than 5 H-bond donors (expressed as the sum of OHs and 
NHs); 
B. The MWT is less than 500; 
C. The LogP is less than 5 (or MLogP is < 4.15); 
D. There are less than 10 H-bond acceptors (expressed as the sum of Ns and 
Os). 
Compound classes that are substrates for biological transporters are exceptions to 
the rule." 
Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, Paul J. Feeney 
"Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings":
• A quick sketch with ChemDraw, conversion to a 
3D structure with Chem3D, and processing by 
QuikProp, reveals that the problem appears to be 
poor cell permeability for this relatively polar 
molecule, with predicted PCaco and PMDCK 
values near 10 nm/s. 
• Free alternative (Chemsketch / PreADME)
(Celebrex) 
Methyl in this position makes it a weaker cox-2 inhibitor, 
but site of metabolic oxidation and ensures an acceptable clearance 
Drug-like-ness
To assist combinatorial chemistry, buy specific compunds
Structural Descriptors: (15 descriptors) 
Molecular Formula, Molecular Weight, Formal Charge, The Number of Rotatable Bonds, The Number of Rigid 
Bonds, The Number of Rings, The Number of Aromatic Rings, The Number of H Bond Acceptors, The 
Number of H Bond Donors, The Number of (+) Charged Groups, The Number of (-) Charged Groups, No. 
single, double, triple, aromatic bonds 
Topological Descriptors:(350 descriptors) 
• Topological descriptors on the adjustancy and distance matrix 
• Count descriptors 
• Kier & Hall molecular connectivity Indices 
• Kier Shape Indices 
• Galvez topological charge Indices 
• Narumi topological index 
• Autocorrelation descriptor of atomic masses, atomic polarizability, Pauling electronegativity and van der 
Waals radius 
• Information content descriptors 
• Electrotopological state index (E-state) 
• Atomic-Level-Based AI topological descriptors 
Physicochemical Descriptor:(10 descriptors) 
AlogP98 (calculated logP), SKlogP (calculated logP), SKlogS in pure water (calculated water solubility), SKlogS in 
buffer system (calculated water solubility),SK vap (calculated vapor pressure), SK bp (calculated boiling 
point), SK mp (calculated meling point), AMR (calculated molecular refractivity), APOL(calculated 
polarizability), Water Solvation Free Energy 
Geometrical Descriptor:(9 descriptors) 
Topological Polar Surface Area, 2D van der Waals Volume, 2D van der Waals Surface Area, 2D van der Waals 
Hydrophobic Surface Area, 2D van der Waals Polar Surface Area, 2D van der Waals H-bond Acceptor Surface 
Area, 2D van der Waals H-bond Donor Surface Area, 2D van der Waals (+) Charged Groups Surface Area, 2D 
van der Waals (-) Charged Groups Surface Area
Drug Discovery: Hit/lead computational approaches 
• What can you do with these descriptors ? 
• Cluster entire chemical library 
– Diversity set 
– Focused set
Drug Discovery: Docking 
• Structure is known, virtual screening -> docking 
• Many different approaches 
– DOCK 
– FlexX 
– Glide 
– GOLD 
• Including conformational sampling of the ligand 
• Problem: 
– host flexibility 
– solvatation 
• Example: Bissantz et al. 
– Hit rate of 10% for single scoring function 
– Up to 70% with triple scoring (bagging)
Drug Discovery: De novo design / rational drug design 
• Given the target site: 
• Docking + structure generator 
• Specialized approach: growing 
substituent on a core 
– LUDI 
– SPROUT 
– BOMB (biochemical and organic model 
builder) 
– SYNOPSIS 
• Problem is the scoring function 
which is different for every protein 
class
Drug Discovery: Novel strategies using bio/cheminformatics 
- HTS ? Chemical space is big (1041) 
- Biased sets/focussed libraries -> bioinformatics !!! 
- How ? Use phylogenetics and known structures to define 
accesible (conserved) functional implicated residues to 
define small molecule pharmacophores (minimal 
requirements) 
- Desciptor search (cheminformatics) to construct/select 
biased compound set 
- ensure serendipity by iterative screening of these 
predesigned sets
Drug Discovery 
Toxigenomics 
Metabogenomics
Drug Discovery: Clinical studies 
• Preclinical - An early phase of development 
including initial safety assessment 
Phase I - Evaluation of clinical pharmacology, 
usually conducted in volunteers 
Phase II - Determination of dose and initial 
evaluation of efficacy, conducted in a small 
number of patients 
Phase III - Large comparative study 
(compound versus placebo and/or established 
treatment) in patients to establish clinical 
benefit and safety 
Phase IV - Post marketing study
Drug Discovery & Development: IND filing
Hapmap
Pharmacogenomics 
Predictive/preventive – systems biology
Sneak preview 
Bioinformatics (re)loaded
Sneak preview 
Bioinformatics (re)loaded 
• Relational datamodels 
– BioSQL (MySQL) 
• Data Visualisation 
– Interface 
• Apache 
• PHP 
• Large Scale Statistics 
– Using R

More Related Content

What's hot

2016 bioinformatics i_wim_vancriekinge_vupload
2016 bioinformatics i_wim_vancriekinge_vupload2016 bioinformatics i_wim_vancriekinge_vupload
2016 bioinformatics i_wim_vancriekinge_vuploadProf. Wim Van Criekinge
 
Personalized Medicine and the Omics Revolution by Professor Mike Snyder
Personalized Medicine and the Omics Revolution by Professor Mike SnyderPersonalized Medicine and the Omics Revolution by Professor Mike Snyder
Personalized Medicine and the Omics Revolution by Professor Mike SnyderThe Hive
 
Genomics & Epigenomics
Genomics & EpigenomicsGenomics & Epigenomics
Genomics & Epigenomicsgumccomm
 
The Microbiome of Research Animals : Implications for Reproducibility, Transl...
The Microbiome of Research Animals : Implications for Reproducibility, Transl...The Microbiome of Research Animals : Implications for Reproducibility, Transl...
The Microbiome of Research Animals : Implications for Reproducibility, Transl...QIAGEN
 
Plant genome sequencing and crop improvement
Plant genome sequencing and crop improvementPlant genome sequencing and crop improvement
Plant genome sequencing and crop improvementRagavendran Abbai
 
Python meetup 2014
Python meetup 2014Python meetup 2014
Python meetup 2014eilosei
 
Functional annotation
Functional annotationFunctional annotation
Functional annotationRavi Gandham
 
2 md2016 annotation
2 md2016 annotation2 md2016 annotation
2 md2016 annotationScott Dawson
 
Aug2015 deanna church analytical validation
Aug2015 deanna church analytical validationAug2015 deanna church analytical validation
Aug2015 deanna church analytical validationGenomeInABottle
 
20140613 Analysis of High Throughput DNA Methylation Profiling
20140613 Analysis of High Throughput DNA Methylation Profiling20140613 Analysis of High Throughput DNA Methylation Profiling
20140613 Analysis of High Throughput DNA Methylation ProfilingYi-Feng Chang
 
BIOL335: Functional genomics
BIOL335: Functional genomicsBIOL335: Functional genomics
BIOL335: Functional genomicsPaul Gardner
 
Clinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceClinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceNikesh Shah
 
Whole genome sequencing of bacteria & analysis
Whole genome sequencing of bacteria & analysisWhole genome sequencing of bacteria & analysis
Whole genome sequencing of bacteria & analysisdrelamuruganvet
 
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...eventi-ITBbari
 
SAGE- Serial Analysis of Gene Expression
SAGE- Serial Analysis of Gene ExpressionSAGE- Serial Analysis of Gene Expression
SAGE- Serial Analysis of Gene ExpressionAashish Patel
 
Next Generation Sequencing Informatics - Challenges and Opportunities
Next Generation Sequencing Informatics - Challenges and OpportunitiesNext Generation Sequencing Informatics - Challenges and Opportunities
Next Generation Sequencing Informatics - Challenges and OpportunitiesChung-Tsai Su
 
SPIN Workshop Microbial Genomics @NIST
SPIN Workshop Microbial Genomics @NISTSPIN Workshop Microbial Genomics @NIST
SPIN Workshop Microbial Genomics @NISTNathan Olson
 

What's hot (20)

2016 bioinformatics i_wim_vancriekinge_vupload
2016 bioinformatics i_wim_vancriekinge_vupload2016 bioinformatics i_wim_vancriekinge_vupload
2016 bioinformatics i_wim_vancriekinge_vupload
 
Genome annotation 2013
Genome annotation 2013Genome annotation 2013
Genome annotation 2013
 
Personalized Medicine and the Omics Revolution by Professor Mike Snyder
Personalized Medicine and the Omics Revolution by Professor Mike SnyderPersonalized Medicine and the Omics Revolution by Professor Mike Snyder
Personalized Medicine and the Omics Revolution by Professor Mike Snyder
 
Genomics & Epigenomics
Genomics & EpigenomicsGenomics & Epigenomics
Genomics & Epigenomics
 
The Microbiome of Research Animals : Implications for Reproducibility, Transl...
The Microbiome of Research Animals : Implications for Reproducibility, Transl...The Microbiome of Research Animals : Implications for Reproducibility, Transl...
The Microbiome of Research Animals : Implications for Reproducibility, Transl...
 
Plant genome sequencing and crop improvement
Plant genome sequencing and crop improvementPlant genome sequencing and crop improvement
Plant genome sequencing and crop improvement
 
Python meetup 2014
Python meetup 2014Python meetup 2014
Python meetup 2014
 
Functional annotation
Functional annotationFunctional annotation
Functional annotation
 
2 md2016 annotation
2 md2016 annotation2 md2016 annotation
2 md2016 annotation
 
Embed Repro Test
Embed Repro TestEmbed Repro Test
Embed Repro Test
 
Aug2015 deanna church analytical validation
Aug2015 deanna church analytical validationAug2015 deanna church analytical validation
Aug2015 deanna church analytical validation
 
20140613 Analysis of High Throughput DNA Methylation Profiling
20140613 Analysis of High Throughput DNA Methylation Profiling20140613 Analysis of High Throughput DNA Methylation Profiling
20140613 Analysis of High Throughput DNA Methylation Profiling
 
BIOL335: Functional genomics
BIOL335: Functional genomicsBIOL335: Functional genomics
BIOL335: Functional genomics
 
Clinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceClinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidance
 
Whole genome sequencing of bacteria & analysis
Whole genome sequencing of bacteria & analysisWhole genome sequencing of bacteria & analysis
Whole genome sequencing of bacteria & analysis
 
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...
Ernesto Picardi – Bioinformatica e genomica comparata: nuove strategie sperim...
 
Introduction to Proteogenomics
Introduction to Proteogenomics Introduction to Proteogenomics
Introduction to Proteogenomics
 
SAGE- Serial Analysis of Gene Expression
SAGE- Serial Analysis of Gene ExpressionSAGE- Serial Analysis of Gene Expression
SAGE- Serial Analysis of Gene Expression
 
Next Generation Sequencing Informatics - Challenges and Opportunities
Next Generation Sequencing Informatics - Challenges and OpportunitiesNext Generation Sequencing Informatics - Challenges and Opportunities
Next Generation Sequencing Informatics - Challenges and Opportunities
 
SPIN Workshop Microbial Genomics @NIST
SPIN Workshop Microbial Genomics @NISTSPIN Workshop Microbial Genomics @NIST
SPIN Workshop Microbial Genomics @NIST
 

Viewers also liked

2015 bioinformatics python_introduction_wim_vancriekinge_vfinal
2015 bioinformatics python_introduction_wim_vancriekinge_vfinal2015 bioinformatics python_introduction_wim_vancriekinge_vfinal
2015 bioinformatics python_introduction_wim_vancriekinge_vfinalProf. Wim Van Criekinge
 
2015 bioinformatics score_matrices_wim_vancriekinge
2015 bioinformatics score_matrices_wim_vancriekinge2015 bioinformatics score_matrices_wim_vancriekinge
2015 bioinformatics score_matrices_wim_vancriekingeProf. Wim Van Criekinge
 
2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekingeProf. Wim Van Criekinge
 
2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_presentProf. Wim Van Criekinge
 
2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinalProf. Wim Van Criekinge
 
Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Prof. Wim Van Criekinge
 
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitterProf. Wim Van Criekinge
 
2015 bioinformatics python_io_wim_vancriekinge
2015 bioinformatics python_io_wim_vancriekinge2015 bioinformatics python_io_wim_vancriekinge
2015 bioinformatics python_io_wim_vancriekingeProf. Wim Van Criekinge
 
Bioinformatica 10-11-2011-t5-database searching
Bioinformatica 10-11-2011-t5-database searchingBioinformatica 10-11-2011-t5-database searching
Bioinformatica 10-11-2011-t5-database searchingProf. Wim Van Criekinge
 
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...Fundación Ramón Areces
 
Bioinformatics t5-databasesearching v2014
Bioinformatics t5-databasesearching v2014Bioinformatics t5-databasesearching v2014
Bioinformatics t5-databasesearching v2014Prof. Wim Van Criekinge
 

Viewers also liked (20)

Bioinformatica p1-perl-introduction
Bioinformatica p1-perl-introductionBioinformatica p1-perl-introduction
Bioinformatica p1-perl-introduction
 
2015 bioinformatics python_introduction_wim_vancriekinge_vfinal
2015 bioinformatics python_introduction_wim_vancriekinge_vfinal2015 bioinformatics python_introduction_wim_vancriekinge_vfinal
2015 bioinformatics python_introduction_wim_vancriekinge_vfinal
 
2015 bioinformatics score_matrices_wim_vancriekinge
2015 bioinformatics score_matrices_wim_vancriekinge2015 bioinformatics score_matrices_wim_vancriekinge
2015 bioinformatics score_matrices_wim_vancriekinge
 
2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge2015 bioinformatics alignments_wim_vancriekinge
2015 bioinformatics alignments_wim_vancriekinge
 
2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present2015 09 imec_wim_vancriekinge_v42_to_present
2015 09 imec_wim_vancriekinge_v42_to_present
 
2015 bioinformatics bio_python
2015 bioinformatics bio_python2015 bioinformatics bio_python
2015 bioinformatics bio_python
 
2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal2014 05 21_personal_genomics_v_n2n_vfinal
2014 05 21_personal_genomics_v_n2n_vfinal
 
Bioinformatics life sciences_2012
Bioinformatics life sciences_2012Bioinformatics life sciences_2012
Bioinformatics life sciences_2012
 
Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014Bioinformatics t7-proteinstructure v2014
Bioinformatics t7-proteinstructure v2014
 
Bioinformatics t8-go-hmm v2014
Bioinformatics t8-go-hmm v2014Bioinformatics t8-go-hmm v2014
Bioinformatics t8-go-hmm v2014
 
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
 
2015 bioinformatics bio_python_part4
2015 bioinformatics bio_python_part42015 bioinformatics bio_python_part4
2015 bioinformatics bio_python_part4
 
2015 bioinformatics python_io_wim_vancriekinge
2015 bioinformatics python_io_wim_vancriekinge2015 bioinformatics python_io_wim_vancriekinge
2015 bioinformatics python_io_wim_vancriekinge
 
Bioinformatica 10-11-2011-t5-database searching
Bioinformatica 10-11-2011-t5-database searchingBioinformatica 10-11-2011-t5-database searching
Bioinformatica 10-11-2011-t5-database searching
 
2012 12 12_adam_v_final
2012 12 12_adam_v_final2012 12 12_adam_v_final
2012 12 12_adam_v_final
 
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...
Jose María Ordovás-El impacto de las ciencias ómicas en la nutrición, la medi...
 
Bioinformatica t3-scoring matrices
Bioinformatica t3-scoring matricesBioinformatica t3-scoring matrices
Bioinformatica t3-scoring matrices
 
2013 03 12_epigenetic_profiling
2013 03 12_epigenetic_profiling2013 03 12_epigenetic_profiling
2013 03 12_epigenetic_profiling
 
Bioinformatics t5-databasesearching v2014
Bioinformatics t5-databasesearching v2014Bioinformatics t5-databasesearching v2014
Bioinformatics t5-databasesearching v2014
 
NXTGNT kick off
NXTGNT kick offNXTGNT kick off
NXTGNT kick off
 

Similar to Bioinformatics t9-t10-biocheminformatics v2014

Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Prof. Wim Van Criekinge
 
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsBioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsProf. Wim Van Criekinge
 
Session 1 part 2
Session 1 part 2Session 1 part 2
Session 1 part 2plmiami
 
A_Pope_RQRM_LeadDisc_June_2016
A_Pope_RQRM_LeadDisc_June_2016A_Pope_RQRM_LeadDisc_June_2016
A_Pope_RQRM_LeadDisc_June_2016Andrew Pope
 
Multiplexing analysis of 1000 approved drugs in PubChem
Multiplexing analysis of 1000 approved drugs in PubChemMultiplexing analysis of 1000 approved drugs in PubChem
Multiplexing analysis of 1000 approved drugs in PubChemChris Southan
 
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...Chanin Nantasenamat
 
Mashing Up Drug Discovery
Mashing Up Drug DiscoveryMashing Up Drug Discovery
Mashing Up Drug DiscoverySciBite Limited
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsKedar Bandekar
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsKedar Bandekar
 
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...Kamel Mansouri
 
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based Platform
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based PlatformNext-Gen Drug Discovery: An Integrated Micro-Droplet Based Platform
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based PlatformLaura Berry
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discoverySAKTHIVEL G
 
Back Rapid lead compounds discovery through high-throughput screening
 Back Rapid lead compounds discovery through high-throughput screening Back Rapid lead compounds discovery through high-throughput screening
Back Rapid lead compounds discovery through high-throughput screeningrita martin
 
MRCT's Centre for Therapeutics Discovery
MRCT's Centre for Therapeutics DiscoveryMRCT's Centre for Therapeutics Discovery
MRCT's Centre for Therapeutics Discoverywarwick_amr
 
Drug Discovery Today: Fighting TB with Technology
Drug Discovery Today: Fighting TB with TechnologyDrug Discovery Today: Fighting TB with Technology
Drug Discovery Today: Fighting TB with Technologyrendevilla
 
Crofton Evolution of Toxicology
Crofton Evolution of ToxicologyCrofton Evolution of Toxicology
Crofton Evolution of ToxicologyKevinCrofton
 
Promiscuous patterns and perils in PubChem and the MLSCN
Promiscuous patterns and perils in PubChem and the MLSCNPromiscuous patterns and perils in PubChem and the MLSCN
Promiscuous patterns and perils in PubChem and the MLSCNJeremy Yang
 
Bigger Data to Increase Drug Discovery
Bigger Data to Increase Drug DiscoveryBigger Data to Increase Drug Discovery
Bigger Data to Increase Drug DiscoverySean Ekins
 

Similar to Bioinformatics t9-t10-biocheminformatics v2014 (20)

Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
Bioinformatics t9-t10-bio cheminformatics-wimvancriekinge_v2013
 
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformaticsBioinformatica 15-12-2011-t9-t10-bio cheminformatics
Bioinformatica 15-12-2011-t9-t10-bio cheminformatics
 
Session 1 part 2
Session 1 part 2Session 1 part 2
Session 1 part 2
 
A_Pope_RQRM_LeadDisc_June_2016
A_Pope_RQRM_LeadDisc_June_2016A_Pope_RQRM_LeadDisc_June_2016
A_Pope_RQRM_LeadDisc_June_2016
 
Multiplexing analysis of 1000 approved drugs in PubChem
Multiplexing analysis of 1000 approved drugs in PubChemMultiplexing analysis of 1000 approved drugs in PubChem
Multiplexing analysis of 1000 approved drugs in PubChem
 
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...
 
Sparsh bioinfo.ppt
Sparsh bioinfo.pptSparsh bioinfo.ppt
Sparsh bioinfo.ppt
 
Mashing Up Drug Discovery
Mashing Up Drug DiscoveryMashing Up Drug Discovery
Mashing Up Drug Discovery
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugs
 
Drug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugsDrug discovery clinical evaluation of new drugs
Drug discovery clinical evaluation of new drugs
 
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
 
Drug discovery anthony crasto
Drug discovery  anthony crastoDrug discovery  anthony crasto
Drug discovery anthony crasto
 
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based Platform
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based PlatformNext-Gen Drug Discovery: An Integrated Micro-Droplet Based Platform
Next-Gen Drug Discovery: An Integrated Micro-Droplet Based Platform
 
Natural products in drug discovery
Natural products in drug discoveryNatural products in drug discovery
Natural products in drug discovery
 
Back Rapid lead compounds discovery through high-throughput screening
 Back Rapid lead compounds discovery through high-throughput screening Back Rapid lead compounds discovery through high-throughput screening
Back Rapid lead compounds discovery through high-throughput screening
 
MRCT's Centre for Therapeutics Discovery
MRCT's Centre for Therapeutics DiscoveryMRCT's Centre for Therapeutics Discovery
MRCT's Centre for Therapeutics Discovery
 
Drug Discovery Today: Fighting TB with Technology
Drug Discovery Today: Fighting TB with TechnologyDrug Discovery Today: Fighting TB with Technology
Drug Discovery Today: Fighting TB with Technology
 
Crofton Evolution of Toxicology
Crofton Evolution of ToxicologyCrofton Evolution of Toxicology
Crofton Evolution of Toxicology
 
Promiscuous patterns and perils in PubChem and the MLSCN
Promiscuous patterns and perils in PubChem and the MLSCNPromiscuous patterns and perils in PubChem and the MLSCN
Promiscuous patterns and perils in PubChem and the MLSCN
 
Bigger Data to Increase Drug Discovery
Bigger Data to Increase Drug DiscoveryBigger Data to Increase Drug Discovery
Bigger Data to Increase Drug Discovery
 

More from Prof. Wim Van Criekinge

2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_uploadProf. Wim Van Criekinge
 
2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_uploadProf. Wim Van Criekinge
 
2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_uploadProf. Wim Van Criekinge
 
2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_uploadProf. Wim Van Criekinge
 
2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_uploadProf. Wim Van Criekinge
 
Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Prof. Wim Van Criekinge
 
2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_uploadProf. Wim Van Criekinge
 
2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_uploadProf. Wim Van Criekinge
 
2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_uploadProf. Wim Van Criekinge
 

More from Prof. Wim Van Criekinge (20)

2020 02 11_biological_databases_part1
2020 02 11_biological_databases_part12020 02 11_biological_databases_part1
2020 02 11_biological_databases_part1
 
2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload2019 03 05_biological_databases_part5_v_upload
2019 03 05_biological_databases_part5_v_upload
 
2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload2019 03 05_biological_databases_part4_v_upload
2019 03 05_biological_databases_part4_v_upload
 
2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload2019 03 05_biological_databases_part3_v_upload
2019 03 05_biological_databases_part3_v_upload
 
2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload2019 02 21_biological_databases_part2_v_upload
2019 02 21_biological_databases_part2_v_upload
 
2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload2019 02 12_biological_databases_part1_v_upload
2019 02 12_biological_databases_part1_v_upload
 
P7 2018 biopython3
P7 2018 biopython3P7 2018 biopython3
P7 2018 biopython3
 
P6 2018 biopython2b
P6 2018 biopython2bP6 2018 biopython2b
P6 2018 biopython2b
 
P4 2018 io_functions
P4 2018 io_functionsP4 2018 io_functions
P4 2018 io_functions
 
P3 2018 python_regexes
P3 2018 python_regexesP3 2018 python_regexes
P3 2018 python_regexes
 
T1 2018 bioinformatics
T1 2018 bioinformaticsT1 2018 bioinformatics
T1 2018 bioinformatics
 
P1 2018 python
P1 2018 pythonP1 2018 python
P1 2018 python
 
Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]Bio ontologies and semantic technologies[2]
Bio ontologies and semantic technologies[2]
 
2018 05 08_biological_databases_no_sql
2018 05 08_biological_databases_no_sql2018 05 08_biological_databases_no_sql
2018 05 08_biological_databases_no_sql
 
2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload2018 03 27_biological_databases_part4_v_upload
2018 03 27_biological_databases_part4_v_upload
 
2018 03 20_biological_databases_part3
2018 03 20_biological_databases_part32018 03 20_biological_databases_part3
2018 03 20_biological_databases_part3
 
2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload2018 02 20_biological_databases_part2_v_upload
2018 02 20_biological_databases_part2_v_upload
 
2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload2018 02 20_biological_databases_part1_v_upload
2018 02 20_biological_databases_part1_v_upload
 
P7 2017 biopython3
P7 2017 biopython3P7 2017 biopython3
P7 2017 biopython3
 
P6 2017 biopython2
P6 2017 biopython2P6 2017 biopython2
P6 2017 biopython2
 

Recently uploaded

SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docxPoojaSen20
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsKarinaGenton
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Concept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfConcept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfUmakantAnnand
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 

Recently uploaded (20)

SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docx
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its Characteristics
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Concept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfConcept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.Compdf
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 

Bioinformatics t9-t10-biocheminformatics v2014

  • 1.
  • 2. FBW 9-12-2014 Wim Van Criekinge
  • 3.
  • 4. Examen <html> <title>Examen Bioinformatica</title> <center> <head> <script> rnd.today=new Date(); rnd.seed=rnd.today.getTime(); function rnd() { rnd.seed = (rnd.seed*9301+49297) % 233280; return rnd.seed/(233280.0); }; function rand(number) { return Math.ceil(rnd()*number); }; </SCRIPT> </head> <body bgcolor="#FFFFFF" text="#00FF00" link="#00FF00"> <script language="JavaScript"> document.write('<table>'); document.write('<tr>'); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98); document.write('<td><a href="index.html" ><img border=0 src="' + rand(713) + '.jpg" width="520" height="360"></a></td>'); rand(98);
  • 5. Comparative Genomics: The biological Rosetta • The keywords can be – genome structure – gene-organisation – known promoter regions – known critical amino acid residues. • Combination of functional modelorganism knowledge • Structure-function • Identify similar areas of biology • Identify orthologous pathways (might have different endpoints)
  • 6.
  • 7. Example: Agro Sequence Genome Known “lethal” genes from worm, drosphila Filter for drugability”, tractibility & novelty
  • 8. Example: Extremophiles Known lipases Filter for “workable”lipases at 90º C Look for species with interesting phenotypes Functional Foods Convert Highly Energetic Monosaccharides to Dextrane Washing Powder additives Sequence Genome Clone and produce in large quantities
  • 9.
  • 10. Drug Discovery: Design new drugs by computer ? Problem: pipeline cost rise linear, NCE steady Money: bypassing difficult, work on attrition Every step requires specific computational tools
  • 11. Drug Discovery: What is a drug ? • Drugs are generally defined as molecules which affect biological processes. • In order to be effective, the molecule must be present in the body at an adequate concentration for it to act at the specific site in the body where it can exert its effect. • Additionally, the molecule must be safe -- that is, metabolized and eliminated from the body without causing injury. • Assumption: next 50 years still a big market in small chemical entities which can be administered orally in form of a pill (in contrast to antibodies) or gene therapy …
  • 12.
  • 13.
  • 14.
  • 15.
  • 16. • Taxol a drug which is an unmodified natural compound, is the exception • Most drugs require “work” -> need for target driven pipeline • Humane genome is available so all target are identified • How to validate (within a given disease area) ?
  • 17. Drug Discovery: What is a target ? • target - a molecule (often a protein) that is instrumental to a disease process (though not necessarily directly involved), which may be targeted with a potential therapeutic. • target identification - identifying a molecule (often a protein) that is instrumental to a disease process (though not necessarily directly involved), with the intention of finding a way to regulate that molecule's activity for therapeutic purposes. • target validation - a crucial step in the drug development process. Following the identification of a potential disease target, target validation verifies that a drug that specifically acts on the target can have a significant therapeutic benefit in the treatment of a given disease.
  • 18. Phenotypic Gap Total # genes # genes with known function Number of genes 1980 1990 2000 2010 Functional Genomics ? More than running chip experiments ! Proposal to prioritize hypothetical protein without annotation, nice for bioinformatics and biologist
  • 19.
  • 20. Where is optimal drug target ? “Optimal” drug target Predict side effect How to correct disease state Side effects ?
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27. Genome-wide RNAi RNAI vector bacteria producing ds RNA for each of the 20.000 genes proprietary nematode responding to RNAi 20.000 responses 20.000 genes insert library
  • 28.
  • 29.
  • 30. Type-II Diabetes Normal insulin signaling fat storage LOW Reduced insulin signaling fat storage HIGH
  • 31. Industrialized knock-downs 20,000 bacteria each containing selected C. elegans gene proprietary C.elegans strains • sensitized to silencing • sensitized to relevant pathway select genes with desired phenotypes
  • 33.
  • 34. Structural Genomics Molecular functions of 26 383 human genes
  • 35.
  • 36. Lipinsky for the target ? Database of all “drugable” human genes
  • 37. Drug Discovery: Design new drugs by computer ?
  • 38. Drug Discovery: Screening definitions screening - the automated examination and testing of libraries of synthetic and/or organic compounds and extracts to identify potential drug leads, based on the compound's binding affinity for a target molecule. screening library - a large collection of compounds with different chemical properties or shapes, generated either by combinatorial chemistry or some other process or by collecting samples with interesting biological properties. High Throughput Screening: Quick and Dirty… from 5000 compounds per day
  • 39. Drug Discovery: Screening Throughput • At the beginning of the 1990s, when the term "high-throughput screening" was coined, a department of 20 would typically be able to screen around 1.5 million samples in a year, each researcher handling around 75,000 samples. Today, four researchers using fully automated robotic technology can screen 50,000 samples a day, or around 2.5 million samples each year.
  • 40. Robotic arm Drug Discovery: HTS – The Wet Lab Distribution 96 / 384 wells Read-out Fluorescence / luminescence Optical Bank for stability
  • 41. Drug Discovery: Chemistry Sources • Available molecules collections from pharma, chemical and agro industry, also from academics (Eastern Europe) • Natural products from fungi, algae, exotic plants, Chinese and ethnobotanic medicines • Combinatorial chemistry: it is the generation of large numbers of diverse chemical compounds (a library) for use in screening assays against disease target molecules. • Computer drug design (from model substrates or X-ray structure)
  • 43. • initial screen established • Compounds screened • IC50s established • Structures verified • Minimum of three independent chemical series to evaluate • Positive in silico PK data Drug Discovery: HIT
  • 44. Drug Discovery: Hit/lead computational approaches • When the structure of the target is unknown, the activity data can be used to construct a pharmacophore model for the positioning of key features like hydrogen-bonding and hydrophobic groups. • Such a model can be used as a template to select the most promising candidates from the library.
  • 45. • lead compound - a potential drug candidate emerging from a screening process of a large library of compounds. • It basically affects specifically a biological process. Mechanism of activity (reversible/ irreversible, kinetics) established • Its is effective at a low concentration: usually nanomolar activity • It is not toxic to live cells • It has been shown to have some in vivo activity • It is chemically feasible. Specificity of key compound(s) from each lead series against selected number of receptors/enzymes • Preliminary PK in vivo (rodent) to establish benchmark for in vitro SAR • In vitro PK data good predictor for in vivo activity • Its is of course New and Original. Drug Discovery: Lead ?
  • 46. Lipinski: « rule of 5 » "In the USAN set we found that the sum of Ns and Os in the molecular formula was greater than 10 in 12% of the compounds. Eleven percent of compounds had a MWT of over 500. Ten percent of compounds had a CLogP larger than 5 (or an MLogP larger than 4.15) and in 8% of compounds the sum of OHs and NHs in the chemical structure was larger than 5. The "rule of 5" states that: poor absorption or permeation is more likely when: A. There are less than 5 H-bond donors (expressed as the sum of OHs and NHs); B. The MWT is less than 500; C. The LogP is less than 5 (or MLogP is < 4.15); D. There are less than 10 H-bond acceptors (expressed as the sum of Ns and Os). Compound classes that are substrates for biological transporters are exceptions to the rule." Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, Paul J. Feeney "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings":
  • 47. • A quick sketch with ChemDraw, conversion to a 3D structure with Chem3D, and processing by QuikProp, reveals that the problem appears to be poor cell permeability for this relatively polar molecule, with predicted PCaco and PMDCK values near 10 nm/s. • Free alternative (Chemsketch / PreADME)
  • 48. (Celebrex) Methyl in this position makes it a weaker cox-2 inhibitor, but site of metabolic oxidation and ensures an acceptable clearance Drug-like-ness
  • 49. To assist combinatorial chemistry, buy specific compunds
  • 50.
  • 51. Structural Descriptors: (15 descriptors) Molecular Formula, Molecular Weight, Formal Charge, The Number of Rotatable Bonds, The Number of Rigid Bonds, The Number of Rings, The Number of Aromatic Rings, The Number of H Bond Acceptors, The Number of H Bond Donors, The Number of (+) Charged Groups, The Number of (-) Charged Groups, No. single, double, triple, aromatic bonds Topological Descriptors:(350 descriptors) • Topological descriptors on the adjustancy and distance matrix • Count descriptors • Kier & Hall molecular connectivity Indices • Kier Shape Indices • Galvez topological charge Indices • Narumi topological index • Autocorrelation descriptor of atomic masses, atomic polarizability, Pauling electronegativity and van der Waals radius • Information content descriptors • Electrotopological state index (E-state) • Atomic-Level-Based AI topological descriptors Physicochemical Descriptor:(10 descriptors) AlogP98 (calculated logP), SKlogP (calculated logP), SKlogS in pure water (calculated water solubility), SKlogS in buffer system (calculated water solubility),SK vap (calculated vapor pressure), SK bp (calculated boiling point), SK mp (calculated meling point), AMR (calculated molecular refractivity), APOL(calculated polarizability), Water Solvation Free Energy Geometrical Descriptor:(9 descriptors) Topological Polar Surface Area, 2D van der Waals Volume, 2D van der Waals Surface Area, 2D van der Waals Hydrophobic Surface Area, 2D van der Waals Polar Surface Area, 2D van der Waals H-bond Acceptor Surface Area, 2D van der Waals H-bond Donor Surface Area, 2D van der Waals (+) Charged Groups Surface Area, 2D van der Waals (-) Charged Groups Surface Area
  • 52. Drug Discovery: Hit/lead computational approaches • What can you do with these descriptors ? • Cluster entire chemical library – Diversity set – Focused set
  • 53. Drug Discovery: Docking • Structure is known, virtual screening -> docking • Many different approaches – DOCK – FlexX – Glide – GOLD • Including conformational sampling of the ligand • Problem: – host flexibility – solvatation • Example: Bissantz et al. – Hit rate of 10% for single scoring function – Up to 70% with triple scoring (bagging)
  • 54. Drug Discovery: De novo design / rational drug design • Given the target site: • Docking + structure generator • Specialized approach: growing substituent on a core – LUDI – SPROUT – BOMB (biochemical and organic model builder) – SYNOPSIS • Problem is the scoring function which is different for every protein class
  • 55. Drug Discovery: Novel strategies using bio/cheminformatics - HTS ? Chemical space is big (1041) - Biased sets/focussed libraries -> bioinformatics !!! - How ? Use phylogenetics and known structures to define accesible (conserved) functional implicated residues to define small molecule pharmacophores (minimal requirements) - Desciptor search (cheminformatics) to construct/select biased compound set - ensure serendipity by iterative screening of these predesigned sets
  • 56. Drug Discovery Toxigenomics Metabogenomics
  • 57.
  • 58. Drug Discovery: Clinical studies • Preclinical - An early phase of development including initial safety assessment Phase I - Evaluation of clinical pharmacology, usually conducted in volunteers Phase II - Determination of dose and initial evaluation of efficacy, conducted in a small number of patients Phase III - Large comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety Phase IV - Post marketing study
  • 59.
  • 60.
  • 61. Drug Discovery & Development: IND filing
  • 65. Sneak preview Bioinformatics (re)loaded • Relational datamodels – BioSQL (MySQL) • Data Visualisation – Interface • Apache • PHP • Large Scale Statistics – Using R